The authors of the above paper regret that the incorrect name was given for the V1a receptor antagonist drug that was administered to rats before MRI experiments. The correct name for the drug is [β-Mercapto-β,β-cyclopentamethylenepropionyl1, O-me-Tyr2,Arg8]-Vasopressin (commercially available through Sigma-Aldrich, St. Louis, MO; Product #V2255) and was not [deamino-Pen(1), O-Me-Tyr, Arg(8)]-Vasopressin. The incorrect name was for a nonselective V1 receptor antagonist that was not used in the study.
Footnotes
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errorsmaybe discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.